In 2013, the rise of vertical Internet platforms broke into the public vision with the concept of medical beauty, and its compound growth rate in the past 5 years was as high as 34.7%, and people's pursuit of beauty was also universalized.
Nowadays, with the continuous change of public aesthetic cognition, people no longer pursue the beauty of the process, but more based on personal characteristics and needs, they are positive to prevent aging and correct aesthetic defects. The "2021 Medical Aesthetic Industry White Paper" released by Yan Institute also confirmed this change. Anti-aging, wrinkle removal and other items have become the first choice of consumers, becoming the largest market growth point.
This change in market demand for beauty has also attracted the attention of the capital market, and a number of listed companies have laid out anti-aging injection products, and top investors such as SoftBank, IDG, Northern Lights, Goldman Sachs, Hillhouse, Zhen Fund, and Yunfeng Fund are competing to lay out here.
The market demand for beauty has shifted from physical filling to natural regeneration anti-aging solutions
At the same time, the anti-aging scheme led by physical filling can no longer meet the needs of beauty seekers, who are more looking forward to a safe and natural regenerative anti-aging program based on science, which substantially delays aging rather than a single physical filling. On the other hand, the same changes are taking place in the field of maxillofacial defect repair, which is mainly based on soft tissue and bone repair, from simple shape repair to biological function regeneration. With the blessing of the two tens of billions of markets, the demand for maxillofacial tissue repair and regeneration has also been expanding. From the upstream point of view, these regenerative filling products are mainly classified into two categories, one is the relatively traditional stimulation regeneration material, and the other is the induced regeneration material represented by ECM collagen.
ECM (Extracellular matrix), the extracellular matrix, can be simply understood as the "soil" of cell growth. Different cells need different soils to nourish and form different tissues, such as bone, cartilage, fat, connective tissue. ECM has fundamentally realized the reshaping of the cell growth environment, and ECM has been applied to a large number of tissue repair products in medicine at home and abroad (see the table below). However, ECM is not fully used in the repair of maxillofacial tissue defects, and all of them are animal-derived extracellular groups.
Application of ECM in the field of medicine
Based on more than ten years of accumulation in the field of regenerative restoration, Meibai Bio has built a tissue-specific extracellular matrix expression platform, and in 2021, it will realize the large-scale production of human ECM extracellular matrix in vitro, become the pioneer of the global industrialization of human ECM regenerative new materials, and apply the raw materials of this technology to the aesthetic regeneration and restoration of maxillofacial tissues, and is committed to becoming the leader in the aesthetic function restoration of maxillofacial tissues.
Accumulate momentum and accumulate energy to plan and move later
The same frequency collision between the strong and the scholar
Leaders in different fields can often produce wonderful "chemical reactions" when they move forward at the same frequency after the collision of ideas. The establishment of Meibai Bio is a one-shot agreement between professionals in three different fields, and it is also an industrialization exploration after the breakthrough of technical barriers.
Dr. Xiao was the founder of the Molecular Biology Platform for Oral and Maxillofacial Surgery at Peking University Stomatological Hospital. During his Ph.D., he began to work on maxillofacial trauma and published several stem cell-related papers in journals such as Cell Host & Microbe, Stem cells, and Theranostics. "From an evolutionary point of view, the symmetry of the face and the standard body shape represent health. The oral and maxillofacial areas of human beings play an important role in vocalization, chewing, aesthetics, breathing, facial expressions and other functions. However, high use and exposure make the oral and maxillofacial areas susceptible to defects or defects. This reduces the patient's quality of life, affects social confidence, and increases the financial burden on themselves and society. Bringing solutions to these problems is also the original intention that led me to found Meibai Biotech. He said.
Dr. Xiao Yi, Co-Founder, Chairman and CTO of Meibai Biotech
In 2019, Dr. Xiao Yi resigned from the Department of Oral and Maxillofacial Surgery of Peking University Stomatological Hospital and met Professor Wei Qiang, an applied materials expert who returned from Germany, and the two explored the industrial application of recycled materials from a scientific research perspective. Subsequently, ms. Mei Jinzhuo, who has many years of experience in the market and operation of multinational pharmaceutical companies, joined ms. Meibai, which promoted the real marketization and industrialization of Meibai Biomaxillofacial regeneration technology.
Maebay Biolab
With its research experience in the field of regenerative filler materials, Meibai Pharmaceuticals quickly built a tissue-specific extracellular matrix expression platform after the first round of financing, and restored the human extracellular matrix composite collagen component to the greatest extent through in vitro tissue engineering technology.
Dr. Xiao Yi revealed that this is the first breakthrough of human-sourceD ECM materials in in vitro tissue engineering in the world, and it is also a voice to the world in the field of regenerative medicine materials in China.
Depth "one kilometer",
Do R&D to production detail control
The core of ECM-induced regeneration, which ultimately comes down to the restructuring of the cell growth environment.
In this regard, the expertise of Wei Qiang and Dr. Xiao Yi was combined. "Only the environmental stimulation of 3D can secrete more collagen cells and extracellular matrix." Dr. Xiao Yi said. They simulated mechanical and biological signals through vectors and media, and developed all of them independently from human mesenchymal stem cell vectors to serum-free media.
"We want to build a moat for our products and businesses through R&D innovation from start to finish. In addition to research and development, the process forging of medical devices is equally important, and quality control is related to quality. He continued.
In 2020, after getting the investment from Danlu Capital, Dr. Xiao Yi told investors that the money should be used to build a factory.
Fully automatic aseptic filling workshop
"We have always demanded ourselves according to the standards of international pharmaceutical companies, so we must establish our own sterile production line." He said. In November 2020, the core team of Meibai Pharmaceutical's GMP plant was completed, and the construction of the aseptic filling plant was completed in June 2021. In August of the same year, the company's first-class products were listed and obtained the A round of financing led by Yahui Capital. The self-developed human mesenchymal stem cell vector makes its ECM materials do not need to import foreign genes through potentially risky methods such as viruses and plasmids, and combined with the same self-developed 3D tissue engineering culture program, the production cost can be reduced and the production capacity can be increased by about 15 times.
It is reported that Meibai Bio has a 1500 square meters of GMP aseptic gel filling workshop, with liquid, gel, lyophilized powder and other dosage forms of sterile production capacity, extracellular matrix composite collagen lyophilized powder annual production value of nearly 1 billion yuan, pre-filled needle and vials annual output of 800,000 pieces.
Width "no boundary",
ECM Material Applications "More Than Beauty"
As for why he chose the productization of the direction of medical aesthetics, Dr. Xiao Yi's answer was very direct: "Enterprises must first survive." However, the application of ECM materials is not limited to medical aesthetics, and the corporate mission of Meibai Bio is also "more than beauty".
Maxillofacial planing hierarchy
ECM is the mechanism of all cell growth. Therefore, in addition to the skin, ECM materials can also be used for the regeneration of periosteum, ligaments, nerve cells, and even heart tissue. Dr. Xiao Yi hopes that in the future, it can fill the market gap filled by human ECM regeneration, and also hopes that ECM can rely on the infinite possibilities of Meibai Bio to play the application field, iterate into mature ECM material medical products, and give back to the society for greater value.
Dr. Xiao Yi said that he hopes that Meibai Bio will become a supplier of high-quality human ECM raw materials, and also become an excellent research and development enterprise of regenerative repair equipment, and can break through more medical scenarios such as oral prosthetic membrane, implant bone induction membrane, muscle, ligament, and extracellular matrix repair in the future.
Maebay Biolab
As a maxillofacial surgeon, Dr. Xiao hopes to apply human-derived ECM materials to maxillofacial soft tissue repair to help patients with congenital cleft lip and palate deformities, as well as patients with acquired maxillofacial tumor resection or deformities secondary to maxillofacial trauma, return to normal appearance. This has always been the biggest driving force of Meibai Bio. At present, the company's corresponding pipeline products are in research and development, registration. Meibai Bio will continue to explore the applicable fields of ECM materials, improve the production capacity of tissue-specific ECM raw materials and preparations, and continuously enhance the medical value of human ECM through the detailed layout of different application scenarios of regenerative medicine.